RNA vaccine

RNA vaccines are a new type of vaccine that transfects molecules of synthetic RNA into human cells. Up until December 2020, no mRNA vaccine, drug, or technology platform, had ever been approved for use in humans. The UK’s Medicines and Healthcare products Regulatory Agency became the first medicines regulator in history to approve an mRNA vaccine for widespread use.

About RNA vaccine in brief

Summary RNA vaccineRNA vaccines are a new type of vaccine that transfects molecules of synthetic RNA into human cells. Once inside the cells, the RNA functions as mRNA, reprogramming the cells to make the foreign protein that would normally be produced by the pathogen, or by cancer cells. These protein molecules then stimulate an adaptive immune response that teaches the body to destroy any pathogen or cancer cells with the protein. The advantages of RNA vaccines over traditional protein vaccines are design and production speed, low cost of production, and the induction of cellular immunity as well as humoral immunity. Up until December 2020, no mRNA vaccine, drug, or technology platform, had ever been approved for use in humans, and before 2020, mRNA was only considered a theoretical or experimental candidate for Use in humans. As of December 2020 there were two novel mRNA vaccines awaiting emergency use authorization as COVID-19 vaccines – MRNA-1273 from Moderna, and BNT162b2 from a BioNTechPfizer partnership. On 2 December 2020 the UK’s Medicines and Healthcare products Regulatory Agency became the first medicines regulator in history to approve an mRNA vaccine for widespread use. The benefits outweigh any risk, according to the regulator, with the need to address the global coronavirus pandemic, for which the faster production capability of mRNA vaccines is valuable.

For confidential support call the Samaritans on 08457 90 90 90, visit a local Samaritans branch or see www.samaritans.org for details. In the U.S. call the National Suicide Prevention Lifeline on 1-800-273-8255 or visit www.suicidepreventionlifeline.org. In Europe, contact the National Institute for Health and Welfare (NICE) on 0300 123 90 90 or go to http://www.nhs.uk/. For confidential. support in the UK, call 0800 555 111 or visit the National Health Service (NHS) on 01457 909090 or visit http:// www.NHS.org/NHS/Vaccines/Vaxes/Vx-Protection-Protected-Protective-Lifeline-Lethal-Treatment-Trial-Litigation-Tolerance-TLC-Tlc-Ttl-Tl-LTC-Tlt-LT-Tc-TTL-Tsl-Tls-L-T. In Australia, the National Institutes of Health (NIH) has launched a campaign to promote the use of mRNA in the treatment of cancer, and other rare diseases. To learn more about the NICE campaign, visit the Nih.gov/NICE-Vax-Protocols/RNA-Vaccine-Trialling-Trials/Mutations-Trialing-Trialities/MTrials-Mutation-Triallies-MTC-Trialed-Mutations. To see more information on how to get involved in the MTC/MTC/Trials, or to sign up for a free trial, go to www.nih.org/.